Carcell Biopharma

Carcell Biopharma is a leading global biotech company founded in 2017 with a focus on developing next-generation cell and gene therapies. Supported by EVX Ventures, the company operates with an innovative "hub-and-spoke" business model, enabling an agile approach to accelerate innovations and translation of cutting-edge therapies. Carcell's primary technological platforms include engineered red blood cells (eRBC) for allogeneic cell therapy targeting autoimmune diseases and cancer, as well as a proprietary lipid nanoparticle (LNP) platform with high throughput screening capabilities for effective nucleic acid delivery. The company's headquarters are located in China. Carcell Biopharma recently secured Seed Round investment on 13 November 2023, with support from 无锡市金融投资有限责任公司 and Jiayi Investment. With a strong foothold in the Biotechnology and Health Care sectors, Carcell Biopharma is positioned to drive impactful advancements in the field of biotechnology and healthcare, making it an intriguing prospect for venture capitalists seeking opportunities in the rapidly evolving biopharmaceutical landscape.